New schizophrenia drug shows promise in early trial

NCT ID NCT07467993

First seen Mar 31, 2026 · Last updated May 13, 2026 · Updated 8 times

Summary

This study tests whether a new drug called GXV813 can safely reduce symptoms of schizophrenia during an acute episode. About 142 hospitalized adults aged 18-65 will receive either GXV813 or a placebo. The main goal is to see if the drug improves scores on a standard symptom scale.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Arch Clinical Trials LLC

    RECRUITING

    St Louis, Missouri, 63141, United States

    Contact

  • CNRI Los Angeles LLC

    RECRUITING

    Pico Rivera, California, 90660, United States

    Contact

  • CenExel iResearch

    RECRUITING

    Decatur, Georgia, 30030, United States

    Contact

  • Pillar Clinical Research LLC

    RECRUITING

    Bentonville, Arkansas, 72712, United States

    Contact

  • Pillar Clinical Research LLC

    RECRUITING

    Chicago, Illinois, 60641, United States

    Contact

  • Segal Institute for Clinical Research

    RECRUITING

    Miami, Florida, 33016, United States

    Contact

  • Uptown Research Institute LLC

    RECRUITING

    Chicago, Illinois, 60640, United States

    Contact

Conditions

Explore the condition pages connected to this study.